pimavanserin - Page 1 | CARLAT PUBLISHING

Expert Q&A

Treatment Challenges in Atypical Parkinsonism

July 1, 2024

Alice Flaherty, MD, PhD.

Neurologist, Massachusetts General Hospital; associate professor of neurology and psychiatry, Harvard Medical School, Cambridge, MA.

Dr. Flaherty has no financial relationships with companies related to this material.

Patients with atypical parkinsonism are less responsive to levodopa, and psychiatric medications can exacerbate motor symptoms. Dr. Flaherty advises how to choose the right treatment in patients with parkinsonism accompanied by psychosis, apathy, anxiety, and depression.

Expert Q&A

Managing Behavioral and Psychological Disturbances in the Nursing Home

April 1, 2024

Maureen C. Nash, MD

Maureen C. Nash, MD.

Medical Director, Providence ElderPlace PACE Oregon. Co-editor, Neurocognitive Behavioral Disorders: An Interdisciplinary Approach to Patient-Centered Care (Springer; 2019). All comments are Dr. Nash’s personal views and not those of any organization.

Dr. Nash has no financial relationships with companies related to this material.

Dr. Maureen Nash shares how CMS regulations for using antipsychotics in nursing homes affects quality of care.

RESEARCH UPDATE

Pimavanserin Improves Negative Symptoms of Schizophrenia

January 1, 2023

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of
schizophrenia.

RESEARCH UPDATE

Can Pimavanserin Treat Psychosis in Patients With Dementia?

October 1, 2022

James Black, MD

James Black, MD. Dr. Black, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study suggests that patients started on pimavanserin for dementia and psychosis should probably continue it to prevent relapse, but we will need more data for clarity given flaws in the study design.

A New Kind of Serotonin Med

April 27, 2020

There's a new crop of psych meds that work through serotonin receptors, but not in the way you'd expect. They range from antipsychotics like lumateperone (Caplyta) to novel therapies for depression and anxiety like psilocybin and MDMA, as well as a few familiar meds like mirtazapine, trazodone, and quetiapine. Learn how the...